Pharming Group
PHAR
3 hedge funds and large institutions have $245K invested in Pharming Group in 2022 Q3 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, reducing their positions, and 0 closing their positions.
36% more capital invested
Capital invested by funds: $180K → $245K (+$65K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$42.9K |
| 2 |
CPA
Cowen Prime Advisors
New York
|
+$2.02K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$626 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPA
1
Cowen Prime Advisors
New York
| $164K | +$2.02K | +200 | +1% |
|
|
2
Morgan Stanley
New York
| $66K | +$42.9K | +4,250 | +170% |
|
|
3
UBS Group
Zurich,
Switzerland
| $15K | +$626 | +62 | +4% |
|
PHAR Hedge Fund Activity: Q3 2022 in Review
3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q3 2022, worth a combined $245K — up 36% from $180K a quarter earlier.
Fund positioning in PHAR was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $42.9K.
- 3 institutional investors held Pharming Group (PHAR) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $245K of Pharming Group stock for Q3 2022, up 36% quarter-over-quarter.
- 0 funds opened new Pharming Group positions in Q3 2022 and 0 closed out.
- The largest Pharming Group buyer in Q3 2022 was Morgan Stanley, an estimated $42.9K added.
Based on aggregated 13F filings for Q3 2022.